Our Company

Our Company Contact Us

       Peptides        Janoshik COA
COA BY Janoshik Ltd. (Independent Analytical Laboratory)

CS-ta110-0929

COA Task Number: 241020
Unique Key: 44XEFGWNFURV
 12 OCT 2026
PURITY

99.759%


PEPTIDE CONTENT

11.50 mg


ENDOTOXI1N

1.531 EU/vial


HEAVY METALS

Pass(Not Detected)

IDENTITY

Confirmed


4
PRODUCTS

Thymosin Alpha-1 10mg

View product specifications, research information, and ordering details.
01

Sample Identification
PRODUCT Thymosin Alpha-1 10mg BATCH CS-ta110-0929
LABORATORY Janoshik Analytical TEST REPORT NOS. #241020· #241021 · #241022
CLIENT Cocer Peptides MANUFACTURER cocerpeptides.com
VERIFICATION KEYS 44XEFGWNFURV · 2N469HGNSFY1 · J9RV5EGP2YIX DOCUMENT TYPE Third-Party Laboratory Test Reports
REPORTING PERIOD 15 Jun – 12 OCT 2026  
02

Purity & Quality Analysis

PURITY 99.759%
HPLC Purity / Test Report #241020
PEPTIDE CONTENT 11.50 mg / vial
Thymosin Alpha-1 Content / Test Report #241020
ENDOTOXIN 1.531 EU / vial
Endotoxin Test / Test Report #241021
Thymosin-Alpha-1-10mg
HEAVY METALS
Arsenic (As) —
Not Detected
Cadmium (Cd) —
Not Detected
Lead (Pb) —
Not Detected
Mercury (Hg) —
Not Detected

Heavy Metals Analysis Test Report #241022

Janoshik COA link
03

Testing Methods & COA

CERTIFICATE OF ANALYSIS
Test Report #241020 (1)
Test Report #241022 (2)
Test Report #241021 (2)
PRODUCT IDENTIFICATION

Thymosin Alpha-1

ANALYSIS SUMMARY
This MOTS-c 10mg batch was independently tested by Janoshik Analytical across three separate test reports. Testing covered peptide content and purity, heavy metals including arsenic, cadmium, lead and mercury, and endotoxin.


The reported results were 11.50 mg/vial peptide content, 99.759% purity, no detected As, Cd, Pb or Hg, and 1.531 EU/vial endotoxin.
PURITY RESULT

99.759%

PEPTIDE CONTENT

11.50 mg / vial

THIRD-PARTY VERIFICATION

Independent third-party testing was completed by Janoshik Analytical for Cocer Peptides batch CS-ta110-0929. The three reports cover peptide content and purity, heavy metals, and endotoxin testing.

TEST REPORT NOS.

REPORTING PERIOD

LAB

BATCH

#241020· #241021 · #241022

15 Jun – 12 OCT 2026

Janoshik Analytical

CS-ta110-0929

04

Test History for Thymosin Alpha-1 10 mg

Independent third-party testing history for Thymosin Alpha-1 10mg.
99.839% Purity

Thymosin Alpha-1 10mg

Janoshik Analytical · 15 JUN 2026

99.699% Purity

Thymosin Alpha-1 10mg

Janoshik Analytical · 21 JUL 2026

99.901% Purity

Thymosin Alpha-1 10mg

Janoshik Analytical · 26 MAY 2026

99.759% Purity

Thymosin Alpha-1 10mg

Janoshik Analytical · 12 JAN 2026

99.818% Purity

Thymosin Alpha-1 10mg

Janoshik Analytical · 30 OCT 2025

· Thymosin Alpha-1 10mg · Batch CS-ta110-0929 · Janoshik Analytical
This laboratory testing information is provided for research reference only. Results apply only to the tested sample(s) associated with the reports shown on this page and may not represent other batches. Products are intended for laboratory research and analytical use only, not for human or veterinary use. Original laboratory reports and verification records should be regarded as the authoritative source.
Cocer Peptides‌™‌ is a source supplier you can always trust.
CONTACT US
  WhatsApp
+852 6904 8891
 
 
  Signal
+852 6904 8891
  Telegram
@CocerService
Telegram Group:
https://t.me/+ritHPUAhhbA0MThh
  Shipping Days
Monday-Saturday /Except Sunday
Orders placed and paid after 12 PM PST are shipped the following business day
Disclaimer: All materials offered by Cocer Peptides are supplied exclusively for legitimate laboratory research, analytical investigation, and in vitro experimental use. They are not offered, labeled, represented, or supplied for human or veterinary administration, consumption, injection, implantation, diagnostic use, therapeutic use, disease prevention, treatment, mitigation, or any other clinical application. Products sold through this website are research materials and are not represented as FDA-approved drug products, medicines, dietary supplements, foods, cosmetics, medical devices, or veterinary products. Cocer Peptides does not provide medical, prescribing, dosing, reconstitution, administration, or clinical-use instructions. Product descriptions, technical information, research articles, references to published scientific literature, and links to third-party materials are provided solely for scientific and educational reference and must not be interpreted as medical advice, treatment recommendations, or evidence of approval for human or animal use. Cocer Peptides does not operate as a pharmacy, does not compound drugs pursuant to patient-specific prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act, and is not registered or represented as an outsourcing facility under Section 503B. Purchasers are responsible for ensuring that all materials are acquired, stored, handled, and used only by appropriately qualified personnel in suitable laboratory environments and in accordance with applicable laws, institutional requirements, and safety procedures. As a condition of purchase, the purchaser represents that the materials will not be used in or administered to humans or animals and will not be relabeled, marketed, transferred, or resold for pharmaceutical, therapeutic, diagnostic, clinical, or veterinary purposes. Cocer Peptides reserves the right to refuse, cancel, restrict, or request additional verification for any order where the intended use, purchaser qualifications, destination, or other circumstances are inconsistent with these research-use requirements or applicable law. Additional conditions governing purchase, handling, shipping, liability, and permitted use are set forth in the applicable Terms and Conditions.
Copyright © 2025-2026 Cocer Peptides Co., Ltd. All Rights Reserved. Sitemap | Privacy Policy